ArticleJournal of gastrointestinal cancer2026
KRAS Mutation Status as a Prognostic Marker and Predictor of Therapy Response in Colorectal Cancer: an NCDB Analysis.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mutations of Kinases and GTPases in Cancers.Cancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKRAS mutation is a prominent biomarker in colorectal cancer (CRC) and is associated with resistance to anti-EGFR therapy in metastatic disease. However, its prognostic value across stages and its association with survival within common treatment pathways remain incompletely defined in large real-world cohorts.
methodsWe performed a retrospective cohort study using the National Cancer Database, identifying 52,534 patients with CRC diagnosed between 2010 and 2021 with documented KRAS mutation status. Demographic, clinicopathological, and treatment variables were analyzed. Overall survival (OS) was evaluated using Kaplan–Meier methods and multivariable Cox proportional hazards models, performed overall and stratified by AJCC stage. Exploratory analyses evaluated the association of KRAS status with OS within stage-specific treatment pathways.
resultsKRAS-mutant tumors comprised 39.9% of the cohort and were more frequently right-sided and metastatic at presentation and were less often poorly differentiated. KRAS mutation was independently associated with worse OS in the overall cohort (HR 1.12). Stage-specific associations were modest but statistically significant in stage II (HR 1.14), stage III (HR 1.16), and stage IV disease (HR 1.07). In exploratory treatment-pathway analyses, KRAS mutation was associated with inferior OS in several common regimens (e.g., surgery + chemotherapy in stage III and stage IV).
conclusionKRAS mutation independently predicts poorer survival in CRC, particularly in earlier stages, and influences outcomes under multiple therapeutic regimens. These findings underscore the importance of KRAS testing to optimize individualized treatment strategies and guide novel interventions targeting KRAS-mutant CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.